anthralin has been researched along with Erythema in 58 studies
Anthralin: An anthracene derivative that disrupts MITOCHONDRIA function and structure and is used for the treatment of DERMATOSES, especially PSORIASIS. It may cause FOLLICULITIS.
anthralin : An anthracene compound derived by the substitution of -OH groups for hydrogen at C-1 and C-8, and with an oxo group at C-9.
Erythema: Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of disease processes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The influence of short-contact anthralin on the therapeutic effect of ultraviolet B irradiation (Sylvania UV-21 tubes) was investigated with the half-body comparison method in fifteen outpatients with plaque-type psoriasis." | 9.06 | Effect of short-contact anthralin therapy on ultraviolet B irradiation of psoriasis. ( Boer, J; Smeenk, G, 1986) |
| "Recent trends in psoriasis therapy favor using lower-strength anthralins." | 9.05 | The effectiveness of low-strength anthralin in psoriasis. A paired comparison study. ( Dawkins, L; Hernandez, AD; Josephs, JA; Marley, WM, 1982) |
| "1 The effect of topical arachidonic acid on anthralin inflammation was studied using sequential measurements of erythema (reflectance photometry) and oedema (calipers)." | 7.67 | Effect of arachidonic acid on anthralin inflammation. ( Lawrence, CM; Shuster, S, 1987) |
| "The effect of tar on anthralin-induced erythema was epicutaneously tested in ten patients." | 7.67 | [Effect of various kinds of tar and tar concentrations on anthralin erythema]. ( Mahrle, G; Schulze, HJ; Steigleder, GK; Wemmer, U, 1986) |
| "Eighteen patients with chronic plaque psoriasis were investigated in two groups to determine the optimal contact time for the application of 2% anthralin, within the range immediate removal to removal at 20 min." | 7.67 | Short contact anthralin in the treatment of psoriasis: a study of different contact times. ( MacDonald, KJ; Marks, J, 1986) |
| "Anthralin erythema dose-response curves were drawn for thirty adult patients of various skin types who had chronic plaque psoriasis." | 7.66 | Relationship between skin type and erythemal response to anthralin. ( Greaves, MW; Maurice, PD, 1983) |
| "Anthralin has been applied in low and high concentrations with and without UV-irradiation in the treatment of psoriasis (Schauder & Mahrle, 1982a,b)." | 7.66 | Anthralin inflammation versus UV-erythema in psoriatics. ( Mahrle, G; Schauder, S, 1983) |
| "Anthralin was applied to psoriatic plaques on one side in the following fashion: anthralin 0." | 6.69 | A comparative study of calcipotriol and anthralin for chronic plaque psoriasis in a day care treatment center. ( Dutz, JP; Lui, H, 1998) |
| " Safety was determined from reports of adverse events and blood chemistry analysis." | 6.69 | The efficacy, safety and tolerance of calcitriol 3 microg/g ointment in the treatment of plaque psoriasis: a comparison with short-contact dithranol. ( Hutchinson, PE; Marks, R; White, J, 2000) |
| "The influence of short-contact anthralin on the therapeutic effect of ultraviolet B irradiation (Sylvania UV-21 tubes) was investigated with the half-body comparison method in fifteen outpatients with plaque-type psoriasis." | 5.06 | Effect of short-contact anthralin therapy on ultraviolet B irradiation of psoriasis. ( Boer, J; Smeenk, G, 1986) |
| "Recent trends in psoriasis therapy favor using lower-strength anthralins." | 5.05 | The effectiveness of low-strength anthralin in psoriasis. A paired comparison study. ( Dawkins, L; Hernandez, AD; Josephs, JA; Marley, WM, 1982) |
| "Anthralin is a safe, effective treatment for psoriasis, but its efficacy is hampered by the side-effects of irritation and staining of the uninvolved skin." | 3.70 | The irritancy of anthralin is inhibited by repeat applications of a subirritant concentration. ( Friedmann, PS; Parslew, R, 1999) |
| "The irritation response to anthralin was studied using the chamber-testing technique in 17 patients with vitiligo." | 3.67 | Increased anthralin irritation response in vitiliginous skin. ( Bos, JD; Buehre, Y; Das, PK; Krieg, SR; Pavel, S; Siddiqui, AH; Westerhof, W, 1989) |
| "1 The effect of topical arachidonic acid on anthralin inflammation was studied using sequential measurements of erythema (reflectance photometry) and oedema (calipers)." | 3.67 | Effect of arachidonic acid on anthralin inflammation. ( Lawrence, CM; Shuster, S, 1987) |
| "In 44 patients with chronic plaque psoriasis anthralin therapy was used as high-strength short-contact therapy in a bilateral comparison of anthralin versus 5% crude coal tar-anthralin combination." | 3.67 | Combined tar-anthralin versus anthralin treatment lowers irritancy with unchanged antipsoriatic efficacy. Modifications of short-contact therapy and Ingram therapy. ( Mahrle, G; Schauder, S; Schulze, HJ; Steigleder, GK, 1987) |
| "The effect of tar on anthralin-induced erythema was epicutaneously tested in ten patients." | 3.67 | [Effect of various kinds of tar and tar concentrations on anthralin erythema]. ( Mahrle, G; Schulze, HJ; Steigleder, GK; Wemmer, U, 1986) |
| "Eighteen patients with chronic plaque psoriasis were investigated in two groups to determine the optimal contact time for the application of 2% anthralin, within the range immediate removal to removal at 20 min." | 3.67 | Short contact anthralin in the treatment of psoriasis: a study of different contact times. ( MacDonald, KJ; Marks, J, 1986) |
| "The effect of topical clobetasol propionate and a 1% topical indomethacin gel which could inhibit UV erythema was measured on anthralin inflammation by change in skin-fold thickness and erythema." | 3.67 | Mechanism of anthralin inflammation. I. Dissociation of response to clobetasol and indomethacin. ( Lawrence, CM; Shuster, S, 1985) |
| "Anthralin erythema dose-response curves were drawn for thirty adult patients of various skin types who had chronic plaque psoriasis." | 3.66 | Relationship between skin type and erythemal response to anthralin. ( Greaves, MW; Maurice, PD, 1983) |
| "In 20 volunteers, we were able to demonstrate experimentally that side-effects of anthralin application on healthy skin development of erythema and pigmentation, can be significantly reduced in a short contact therapy, in comparison to a longterm treatment." | 3.66 | [Side effects of anthralin and its 2 main impurities on healthy skin]. ( Puschmann, M; Schmersahl, P, 1983) |
| "Anthralin has been applied in low and high concentrations with and without UV-irradiation in the treatment of psoriasis (Schauder & Mahrle, 1982a,b)." | 3.66 | Anthralin inflammation versus UV-erythema in psoriatics. ( Mahrle, G; Schauder, S, 1983) |
| "Anthralin was applied to psoriatic plaques on one side in the following fashion: anthralin 0." | 2.69 | A comparative study of calcipotriol and anthralin for chronic plaque psoriasis in a day care treatment center. ( Dutz, JP; Lui, H, 1998) |
| " We used low-dose narrow-band UVB phototherapy, combined with balneotherapy, short-contact anthralin, liquor carbonis detergens and calcipotriol for treatment of psoriatic patients in our day care centre." | 2.69 | Low-dose narrow-band UVB phototherapy combined with topical therapy is effective in psoriasis and does not inhibit systemic T-cell activation. ( Bos, JD; de Rie, MA; Out, TA, 1998) |
| " Safety was determined from reports of adverse events and blood chemistry analysis." | 2.69 | The efficacy, safety and tolerance of calcitriol 3 microg/g ointment in the treatment of plaque psoriasis: a comparison with short-contact dithranol. ( Hutchinson, PE; Marks, R; White, J, 2000) |
| " Our purpose is to compare the rates of adverse events associated with different topical psoriasis treatments." | 2.42 | A systematic review of adverse effects associated with topical treatments for psoriasis. ( Bruner, CR; Feldman, SR; Fleischer, AB; Ventrapragada, M, 2003) |
| "Anthralin was first synthesized in 1916." | 2.36 | Anthralin: historical and current perspectives. ( Andre, P; Ashton, RE; Lowe, NJ; Whitefield, M, 1983) |
| "Anthralin and UVB were then applied to the gel-treated skin and the anthralin- and UVB-induced erythema and oedema were measured at 2, 6, 24 and 48 h using Harpenden callipers and a reflectance erythrometer." | 1.28 | The effect of indomethacin on anthralin inflammation. ( Lawrence, C; Ramsay, B; Rice, N, 1992) |
| "8 of these 13 reacted with blister formation after exposure to 0." | 1.27 | Irritant potential of dithranol. ( Haustein, UF; Lohrisch, I, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 40 (68.97) | 18.7374 |
| 1990's | 14 (24.14) | 18.2507 |
| 2000's | 4 (6.90) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bruner, CR | 1 |
| Feldman, SR | 1 |
| Ventrapragada, M | 1 |
| Fleischer, AB | 1 |
| HEITE, HJ | 1 |
| KLEINHANS, D | 1 |
| Waterston, K | 1 |
| Naysmith, L | 1 |
| Rees, JL | 2 |
| Finnen, MJ | 1 |
| Lawrence, CM | 3 |
| Shuster, S | 3 |
| Mustakallio, KK | 4 |
| Brandt, H | 1 |
| Kolari, PJ | 2 |
| Göransson, AM | 1 |
| Ashton, RE | 1 |
| Andre, P | 1 |
| Lowe, NJ | 1 |
| Whitefield, M | 2 |
| Farber, EM | 1 |
| Maurice, PD | 1 |
| Greaves, MW | 2 |
| Puschmann, M | 2 |
| Barr, RM | 1 |
| Misch, KJ | 1 |
| Hensby, CN | 2 |
| Mallet, AI | 1 |
| Schulze, HJ | 3 |
| Kingston, T | 1 |
| Marks, R | 2 |
| Schmersahl, P | 1 |
| Schauder, S | 2 |
| Mahrle, G | 3 |
| Marley, WM | 1 |
| Hernandez, AD | 1 |
| Josephs, JA | 1 |
| Dawkins, L | 1 |
| Misch, K | 1 |
| Davies, M | 1 |
| Greaves, M | 1 |
| Coutts, A | 1 |
| Juhlin, L | 1 |
| Stüttgen, G | 1 |
| Flesch, U | 1 |
| Siebel, JT | 1 |
| van der Valk, PG | 3 |
| Zarafonitis, G | 1 |
| Snater, E | 2 |
| Janssen, EA | 1 |
| van de Kerkhof, PC | 5 |
| Healy, E | 1 |
| Reynolds, NJ | 1 |
| Smith, MD | 1 |
| Campbell, C | 1 |
| Farr, PM | 2 |
| Shenoy, SD | 1 |
| Wali, I | 1 |
| Srinivas, CR | 1 |
| Schiavi, ME | 1 |
| Belletti, B | 1 |
| Seidenari, S | 1 |
| Dutz, JP | 1 |
| Lui, H | 1 |
| de Rie, MA | 1 |
| Out, TA | 1 |
| Bos, JD | 2 |
| Prins, M | 1 |
| Swinkels, OQ | 1 |
| Kolkman, EG | 1 |
| Wuis, EW | 1 |
| Hekster, YA | 1 |
| Parslew, R | 1 |
| Friedmann, PS | 1 |
| Hutchinson, PE | 1 |
| White, J | 1 |
| Fluhr, JW | 1 |
| Kuss, O | 1 |
| Diepgen, T | 1 |
| Lazzerini, S | 1 |
| Pelosi, A | 1 |
| Gloor, M | 2 |
| Berardesca, E | 1 |
| Gehring, W | 1 |
| Ghyczy, M | 1 |
| Scheer, T | 1 |
| Röding, J | 1 |
| Ramsay, B | 1 |
| Rice, N | 1 |
| Lawrence, C | 1 |
| Zackheim, HS | 1 |
| Timmerman, MG | 2 |
| Mier, PD | 1 |
| de Mare, S | 1 |
| Calis, N | 1 |
| den Hartog, G | 1 |
| van Erp, PE | 1 |
| Fokkink, HJ | 1 |
| Christensen, OB | 1 |
| Holst, R | 1 |
| Hradil, E | 1 |
| Brolund, L | 1 |
| Westerhof, W | 1 |
| Buehre, Y | 1 |
| Pavel, S | 1 |
| Das, PK | 1 |
| Krieg, SR | 1 |
| Siddiqui, AH | 1 |
| Diffey, BL | 1 |
| Marks, JM | 1 |
| Kudejko, J | 1 |
| Lecewicz-Toruń, B | 1 |
| Chibowska, M | 1 |
| Tyszlukiewicz, D | 1 |
| Kuczyńska, L | 1 |
| Nestorowicz, B | 1 |
| Steigleder, GK | 2 |
| Shroot, B | 1 |
| Chatelus, A | 1 |
| Cavey, D | 1 |
| Allec, J | 1 |
| Maignan, J | 1 |
| Richter, G | 1 |
| Barth, J | 2 |
| Boer, J | 1 |
| Smeenk, G | 1 |
| Wemmer, U | 1 |
| Young, E | 1 |
| Haustein, UF | 1 |
| Lohrisch, I | 1 |
| Hanhijärvi, H | 1 |
| Nevalainen, T | 1 |
| Männistö, P | 1 |
| MacDonald, KJ | 1 |
| Marks, J | 1 |
| Gupta, AK | 1 |
| Ellis, CN | 1 |
| Goldfarb, MT | 1 |
| Voorhees, JJ | 1 |
| Heller, G | 1 |
| Wozel, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Spray® and Vectical Ointment® in the Treatment of Plaque Psoriasis[NCT01205880] | Phase 4 | 12 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Effect of an Emollient Cream Containing 0.5% Cannabidiol and 1% Hemp Oil in the Hydration and Erythema of the Skin[NCT04045314] | 49 participants (Actual) | Interventional | 2019-08-15 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for anthralin and Erythema
| Article | Year |
|---|---|
A systematic review of adverse effects associated with topical treatments for psoriasis.
Topics: Administration, Topical; Adrenal Cortex Hormones; Anthralin; Calcitriol; Coal Tar; Dermatologic Agen | 2003 |
Anthralin: historical and current perspectives.
Topics: Anthracenes; Anthralin; Cell Division; Chemistry; Cyclic AMP; Cyclic GMP; DNA Replication; Drug Admi | 1983 |
15 trials available for anthralin and Erythema
| Article | Year |
|---|---|
Physiological variation in the erythemal response to ultraviolet radiation and photoadaptation.
Topics: Adaptation, Physiological; Adolescent; Adult; Anthralin; Anti-Inflammatory Agents; Dose-Response Rel | 2004 |
Inhibition of dithranol inflammation by free-radical scavengers.
Topics: Administration, Topical; Adult; Aged; Anthracenes; Anthralin; Butylated Hydroxyanisole; Diterpenes; | 1984 |
The effectiveness of low-strength anthralin in psoriasis. A paired comparison study.
Topics: Administration, Oral; Anthracenes; Anthralin; Double-Blind Method; Erythema; Female; Humans; Male; P | 1982 |
Transepidermal water vapour loss is not increased during and following dithranol irritation.
Topics: Adult; Anthralin; Colorimetry; Epidermis; Erythema; Female; Humans; Male; Skin; Time Factors; Water | 1995 |
A comparative study of calcipotriol and anthralin for chronic plaque psoriasis in a day care treatment center.
Topics: Administration, Topical; Adolescent; Adult; Aged; Ambulatory Care Facilities; Anthralin; Anti-Inflam | 1998 |
Low-dose narrow-band UVB phototherapy combined with topical therapy is effective in psoriasis and does not inhibit systemic T-cell activation.
Topics: Administration, Topical; Adolescent; Adult; Aged; Anthralin; Anti-Inflammatory Agents; Balneology; C | 1998 |
Skin irritation by dithranol cream. A blind study to assess the role of the cream formulation.
Topics: Administration, Topical; Adult; Anthralin; Anti-Inflammatory Agents; Colorimetry; Erythema; Female; | 1998 |
The efficacy, safety and tolerance of calcitriol 3 microg/g ointment in the treatment of plaque psoriasis: a comparison with short-contact dithranol.
Topics: Administration, Topical; Adult; Anthralin; Anti-Inflammatory Agents; Calcitriol; Eczema; Emulsions; | 2000 |
The effect of clobetasol-17-propionate and crude coal tar on dithranol-induced inflammation. A clinical and biochemical study.
Topics: Adolescent; Adult; Alkaline Phosphatase; Anthralin; Clobetasol; Coal Tar; Drug Therapy, Combination; | 1990 |
The relevance of salicylic acid in the treatment of plaque psoriasis with dithranol creams.
Topics: Adolescent; Adult; Anthralin; DNA; Double-Blind Method; Erythema; Female; Flow Cytometry; Humans; Ke | 1988 |
Clinical response and side-effects in the treatment of psoriasis with UV-B and -A novel dithranol formulation.
Topics: Adolescent; Adult; Aged; Anthralin; Combined Modality Therapy; Drug Compounding; Erythema; Female; H | 1989 |
Phototherapy and dithranol treatment of psoriasis: new lamps for old.
Topics: Adolescent; Adult; Anthralin; Clinical Trials as Topic; Combined Modality Therapy; Erythema; Female; | 1987 |
[Treatment of psoriasis with erythema dose of cygnoline and irradiation with ultraviolet rays].
Topics: Adolescent; Adult; Anthralin; Erythema; Female; Humans; Male; Middle Aged; Psoriasis; PUVA Therapy; | 1986 |
Effect of short-contact anthralin therapy on ultraviolet B irradiation of psoriasis.
Topics: Adolescent; Adult; Aged; Anthracenes; Anthralin; Combined Modality Therapy; Erythema; Female; Humans | 1986 |
Treatment of psoriasis with dithranol cream compared with dithranol paste.
Topics: Administration, Topical; Anthralin; Dosage Forms; Erythema; Evaluation Studies as Topic; Humans; Pso | 1986 |
41 other studies available for anthralin and Erythema
| Article | Year |
|---|---|
[On cignolin erythema swelling in some dermatoses].
Topics: Anthralin; Dermatology; Edema; Erythema; Skin Diseases | 1961 |
Irritation and staining by dithranol (anthralin) and related compounds: II. Structure-activity relationships among 10-meso-substituted acyl analogues.
Topics: Anthracenes; Anthralin; Drug Eruptions; Edema; Erythema; Humans; Psoriasis; Skin; Structure-Activity | 1980 |
Irritation and staining by dithranol (anthralin) and related compounds. III. Cumulative irritancy and staining during repeated chamber testing.
Topics: Anthracenes; Anthralin; Erythema; Humans; Irritants; Skin; Skin Tests | 1983 |
Irritation and staining by dithranol (anthralin) and related compounds. IV. Visual estimation of erythema compared with contact thermometry and laser Doppler flowmetry.
Topics: Anthracenes; Anthralin; Dose-Response Relationship, Drug; Erythema; Humans; Lasers; Psoriasis; Rheol | 1983 |
Irritation and staining by dithranol (anthralin) and related compounds. V. Short-contact and tape-stripping experiments with dithranol and butantrone.
Topics: Anthracenes; Anthralin; Drug Administration Schedule; Erythema; Humans; Psoriasis; Skin; Staining an | 1984 |
Topical treatment of psoriasis with dithranol.
Topics: Administration, Topical; Anthracenes; Anthralin; Combined Modality Therapy; Drug Administration Sche | 1984 |
Relationship between skin type and erythemal response to anthralin.
Topics: Adult; Anthracenes; Anthralin; Dose-Response Relationship, Drug; Erythema; Female; Humans; Male; Pso | 1983 |
[Anthralin erythema: effect of concentration, contact time, oxidation products and corticosteroids. Clinical, reflection photometry and electron microscopy studies].
Topics: Adrenal Cortex Hormones; Anthracenes; Anthralin; Erythema; Humans; Microscopy, Electron; Photometry; | 1983 |
Arachidonic acid and prostaglandin levels in dithranol erythema: time course study.
Topics: Adult; Aged; Anthracenes; Anthralin; Arachidonic Acids; Erythema; Female; Humans; Male; Middle Aged; | 1983 |
[Suppression of cignolin-induced erythema by tar].
Topics: Anthracenes; Anthralin; Coal Tar; Dermatologic Agents; Dose-Response Relationship, Drug; Drug Combin | 1984 |
Irritant reactions to dithranol in normal subjects and psoriatic patients.
Topics: Anthracenes; Anthralin; Dose-Response Relationship, Drug; Erythema; Humans; Indomethacin; Irritants; | 1983 |
[Side effects of anthralin and its 2 main impurities on healthy skin].
Topics: Anthracenes; Anthralin; Anthraquinones; Dose-Response Relationship, Drug; Erythema; Humans; Oxidatio | 1983 |
Anthralin inflammation versus UV-erythema in psoriatics.
Topics: Anthracenes; Anthralin; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Ery | 1983 |
Pharmacological studies of anthralin erythema.
Topics: Anthracenes; Anthralin; Aspirin; Betamethasone Valerate; Chlorpheniramine; Erythema; Female; Humans; | 1981 |
Factors influencing anthralin erythema.
Topics: Anthracenes; Anthralin; Erythema; Humans; Psoriasis; Skin; Ultraviolet Therapy | 1981 |
Thermographic analyses of anthralin and UV-B exposed human skin.
Topics: Anthracenes; Anthralin; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Ery | 1981 |
Quantification of biophysical properties of the skin.
Topics: Anthralin; Biophysical Phenomena; Biophysics; Body Water; Dermatitis, Irritant; Erythema; Humans; Sk | 1995 |
Dissociation of erythema and p53 protein expression in human skin following UVB irradiation, and induction of p53 protein and mRNA following application of skin irritants.
Topics: Adult; Aged; Aged, 80 and over; Anthralin; Dermatitis, Irritant; Erythema; Female; Gene Expression R | 1994 |
Dithranol-induced erythema sparing hypopigmented lesions of pityriasis versicolor.
Topics: Adult; Anthralin; Erythema; Humans; Male; Tinea Versicolor | 1993 |
Ultrasound description and quantification of irritant reactions induced by dithranol at different concentrations. A comparison with visual assessment and colorimetric measurements.
Topics: Administration, Topical; Adolescent; Adult; Analysis of Variance; Anthralin; Anti-Inflammatory Agent | 1996 |
The irritancy of anthralin is inhibited by repeat applications of a subirritant concentration.
Topics: Adaptation, Physiological; Administration, Topical; Anthralin; Anti-Inflammatory Agents; Case-Contro | 1999 |
Testing for irritation with a multifactorial approach: comparison of eight non-invasive measuring techniques on five different irritation types.
Topics: Adult; Analysis of Variance; Anthralin; Calorimetry; Dermatitis, Irritant; Erythema; Female; Humans; | 2001 |
Enhancement of the penetration of dithranol and increase of effect of dithranol on the skin by liposomes.
Topics: Adult; Anthralin; Colorimetry; Drug Carriers; Erythema; Female; Humans; Liposomes; Male; Petrolatum; | 1992 |
The effect of indomethacin on anthralin inflammation.
Topics: Administration, Topical; Adolescent; Adult; Aged; Anthralin; Dermatitis, Contact; Edema; Erythema; F | 1992 |
Evaluation of anthralin for mycosis fungoides.
Topics: Adult; Aged; Anthralin; Erythema; Female; Humans; Male; Middle Aged; Mycosis Fungoides; Ointments; S | 1992 |
Studies on the time course of dithranol-induced inflammation by quantification of alkaline phosphatase.
Topics: Adult; Alkaline Phosphatase; Anthralin; Biopsy; Erythema; Female; Free Radicals; Humans; Male; Patch | 1990 |
Irritancy of dithranol in normally pigmented and depigmented skin of patients with vitiligo.
Topics: Adult; Anthralin; Dose-Response Relationship, Drug; Erythema; Female; Humans; Irritants; Male; Middl | 1989 |
Increased anthralin irritation response in vitiliginous skin.
Topics: Adult; Anthralin; Cell Count; Erythema; Female; Humans; Irritants; Male; Middle Aged; Patch Tests; S | 1989 |
Effect of arachidonic acid on anthralin inflammation.
Topics: Administration, Topical; Adult; Aged; Anthralin; Arachidonic Acid; Arachidonic Acids; Diterpenes; Ed | 1987 |
Combined tar-anthralin versus anthralin treatment lowers irritancy with unchanged antipsoriatic efficacy. Modifications of short-contact therapy and Ingram therapy.
Topics: Administration, Topical; Anthralin; Coal Tar; Drug Combinations; Erythema; Humans; Psoriasis; Ultrav | 1987 |
In vitro and in vivo antiinflammatory activities of C10 substituted anthralin derivatives.
Topics: Animals; Anthralin; Anti-Inflammatory Agents, Non-Steroidal; Chemotaxis, Leukocyte; Dermatitis, Cont | 1987 |
[Potential factors influencing dithranol erythema].
Topics: Adult; Anthracenes; Anthralin; Erythema; Female; Humans; Male; Patch Tests; Psoriasis; Skin | 1986 |
[Effect of various kinds of tar and tar concentrations on anthralin erythema].
Topics: Adolescent; Adult; Aged; Anthracenes; Anthralin; Coal Tar; Dose-Response Relationship, Drug; Erythem | 1986 |
Irritant potential of dithranol.
Topics: Anthralin; Blister; Dermatitis, Contact; Dose-Response Relationship, Drug; Drug Incompatibility; Ery | 1986 |
Degradation of anthralin by coal tar.
Topics: Anthralin; Coal Tar; Drug Synergism; Erythema; Humans | 1987 |
A six month dermal irritation test with anthralins in the Göttingen miniature swine.
Topics: Animals; Anthracenes; Anthralin; Erythema; Female; Male; Random Allocation; Skin; Swine; Swine, Mini | 1985 |
Short contact anthralin in the treatment of psoriasis: a study of different contact times.
Topics: Adolescent; Adult; Aged; Anthracenes; Anthralin; Child; Chronic Disease; Color; Drug Administration | 1986 |
Woronoff ring during anthralin therapy for psoriasis.
Topics: Anthracenes; Anthralin; Erythema; Humans; Middle Aged; Pigmentation Disorders; Psoriasis; Skin | 1986 |
Mechanism of anthralin inflammation. I. Dissociation of response to clobetasol and indomethacin.
Topics: Adult; Aged; Anthracenes; Anthralin; Betamethasone; Clobetasol; Dermatitis, Contact; Edema; Erythema | 1985 |
[Reduction of erythema by the addition of bituminous coal tar in anthralin short-term therapy].
Topics: Adolescent; Adult; Aged; Anthracenes; Anthralin; Coal Tar; Drug Therapy, Combination; Erythema; Fema | 1985 |
[Suppression of dithranol erythema by the addition of tar in short-term therapy].
Topics: Anthracenes; Anthralin; Drug Therapy, Combination; Erythema; Humans; Psoriasis; Tars | 1985 |